Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Y. Ryabuhina

UPDATED SAFETY AND EFFICACY RESULTS OF «HLMoscow 1-3» STUDY FOR THE 147 UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA

Hematological Oncology

English

Related publications

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (Apvd) for Patients With Untreated Classical Hodgkin Lymphoma

Hematological Oncology

English

Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

English

Ebeacopp With or Without Rituximab in Interim-Pet-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG Hd18 Trial

Hematological Oncology

English

Brentuximab Vedotin Followed by ABVD +/− Radiotherapy in Patients With Previously Untreated Hodgkin Lymphoma: Final Results of a Pilot Phase II Study

Haematologica

Hematology

2015

English

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Journal of Clinical Oncology

English

Mortality Rates Remain Increased in Young Patients With Classical Hodgkin Lymphoma Even After Years in Remission: Results From a Nordic Lymphoma Group Study

Hematological Oncology

English

Expression of PD-1 and PD-L1 Increase in Consecutive Biopsies in Patients With Classical Hodgkin Lymphoma

PLoS ONE

Multidisciplinary

2018

English

Lymphocyte-Rich Classical Hodgkin Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology

English

Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Y. Ryabuhina

UPDATED SAFETY AND EFFICACY RESULTS OF «HLMoscow 1-3» STUDY FOR THE 147 UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA

Related publications

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (Apvd) for Patients With Untreated Classical Hodgkin Lymphoma

Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

Ebeacopp With or Without Rituximab in Interim-Pet-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG Hd18 Trial

Brentuximab Vedotin Followed by ABVD +/− Radiotherapy in Patients With Previously Untreated Hodgkin Lymphoma: Final Results of a Pilot Phase II Study

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Mortality Rates Remain Increased in Young Patients With Classical Hodgkin Lymphoma Even After Years in Remission: Results From a Nordic Lymphoma Group Study

Expression of PD-1 and PD-L1 Increase in Consecutive Biopsies in Patients With Classical Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma

Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study